NCT06260267View on ClinicalTrials.gov

A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 12, 2024

Primary Completion Date

January 15, 2026

Study Completion Date

January 15, 2026

Conditions
Ulcerative Colitis
Interventions
DRUG

Microbiota suspension

Microbiota suspension

DRUG

Microbiota capsule

Microbiota capsule

DRUG

Placebo suspension

Placebo suspension

DRUG

Placebo capsule

Placebo capsule

Trial Locations (10)

32256

Ferring Investigational Site, Jacksonville

32763

Ferring Investigational Site, Orange City

34452

Ferring Investigational Site, Inverness

60026

Ferring Investigational Site, Glenview

60031

Ferring Investigational Site, Gurnee

71105

Ferring Investigational Site, Shreveport

72117

Ferring Investigational Site, North Little Rock

73102

Ferring Investigational Site, Oklahoma City

06518

Ferring Investigational Site, Hamden

02115

Ferring Investigational Site, Boston

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT06260267 - A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis | Biotech Hunter | Biotech Hunter